Our Pricing

Wegovy Weight Loss Injection: Clinical Evidence and UK Availability

Wegovy weight loss injection (semaglutide 2.4mg) represents a clinically proven GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Manufactured by Novo Nordisk and backed by the landmark STEP clinical trial programme, this once-weekly subcutaneous injection has demonstrated average weight reductions of 15-17% over 68 weeks when combined with lifestyle interventions [1]. As a prescription-only medicine dispensed by UK-registered pharmacies, Wegovy requires clinical assessment by a qualified prescriber to ensure suitability and safety.

How Wegovy Weight Loss Injection Works in the Body

Wegovy weight loss injection contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of naturally occurring GLP-1 hormones in the body. When administered subcutaneously once weekly, semaglutide binds to GLP-1 receptors in the brain's appetite regulation centres, particularly the hypothalamus, reducing hunger signals and increasing feelings of satiety after meals [2]. This mechanism differs fundamentally from stimulant-based appetite suppressants, as it works with the body's existing hormonal pathways rather than artificially stimulating the central nervous system.

The pharmacological action extends beyond appetite regulation. Clinical studies demonstrate that semaglutide slows gastric emptying, meaning food remains in the stomach longer, prolonging the sensation of fullness between meals [2]. Additionally, the medication influences reward pathways associated with food intake, potentially reducing cravings for high-calorie foods. The 2.4mg dose used in Wegovy represents the optimal therapeutic concentration identified through dose-ranging studies in the STEP trial programme, balancing efficacy with tolerability across diverse patient populations.

GLP-1 Receptor Mechanism and Metabolic Effects

Beyond weight reduction, Wegovy weight loss injection produces favourable metabolic effects documented in clinical trials. Patients typically experience improvements in glycaemic control, with reductions in HbA1c levels even in those without diabetes, alongside improvements in blood pressure and lipid profiles [1]. These cardiometabolic benefits contribute to the overall health improvements observed in clinical practice, though the primary indication remains weight management rather than diabetes treatment (for which lower semaglutide doses are prescribed under different brand names).

Clinical Evidence: STEP Trials for Wegovy Weight Loss Injection

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme provides the robust evidence base supporting Wegovy weight loss injection. The pivotal STEP 1 trial enrolled 1,961 adults with obesity or overweight with comorbidities, randomising participants to receive either semaglutide 2.4mg or placebo weekly for 68 weeks, alongside lifestyle interventions [1]. Results demonstrated that participants receiving Wegovy achieved an average weight loss of 14.9% of initial body weight, compared to 2.4% in the placebo group—a clinically and statistically significant difference that exceeded outcomes seen with previous weight management medications.

Subsequent STEP trials examined specific populations and scenarios. STEP 2 focused on individuals with type 2 diabetes, STEP 3 incorporated intensive behavioural therapy, and STEP 4 assessed weight maintenance after initial weight loss [3]. Across all trials, Wegovy weight loss injection consistently demonstrated superior efficacy compared to placebo, with approximately 85% of participants achieving at least 5% weight loss—the threshold associated with meaningful health improvements—and nearly 70% achieving 10% or greater weight reduction [3]. These outcomes positioned semaglutide 2.4mg as one of the most effective pharmacological interventions for obesity management currently available in the UK.

Wegovy Weight Loss Injection Dosing Schedule and Administration

Wegovy weight loss injection follows a graduated dose-escalation protocol designed to optimise gastrointestinal tolerability whilst achieving therapeutic effect. Treatment commences at 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [4]. This titration schedule, established through clinical trials, significantly reduces the incidence and severity of nausea and vomiting—the most common adverse effects associated with GLP-1 receptor agonists—by allowing the digestive system to adapt gradually to the medication's effects on gastric motility.

Each Wegovy weight loss injection is administered subcutaneously into the abdomen, thigh, or upper arm using a pre-filled FlexTouch pen supplied by Novo Nordisk. Patients receive comprehensive training on injection technique during their initial consultation, though the pen device is designed for intuitive self-administration. The once-weekly dosing schedule offers practical advantages over daily injections, improving adherence rates documented in real-world effectiveness studies [4]. Injections should occur on the same day each week, though the specific time of day is flexible—a feature that accommodates varying work schedules and lifestyles.

Storage and Handling Requirements

Proper storage maintains the stability and efficacy of Wegovy weight loss injection throughout its shelf life. Unused pens must be refrigerated at 2-8°C until first use, protected from light in the original carton. Once in use, pens may be stored at room temperature (below 30°C) or continued refrigeration for up to 6 weeks, offering flexibility for patients who travel or prefer not to inject cold medication [4]. Pens should never be frozen, and if freezing occurs, the medication must be discarded as freezing denatures the semaglutide protein structure.

Who Can Use Wegovy Weight Loss Injection: Eligibility Criteria

Wegovy weight loss injection is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [5]. These criteria align with NICE guidance on pharmacological interventions for obesity management and reflect the populations studied in the STEP clinical trials. Prescribers assess individual suitability during clinical consultations, considering medical history, current medications, and contraindications before approving treatment.

Certain conditions preclude the use of Wegovy weight loss injection. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and hypersensitivity to semaglutide or excipients [5]. The medication is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation due to the long half-life of semaglutide. Patients with severe gastrointestinal disease, including gastroparesis, require careful evaluation as Wegovy affects gastric emptying. Those with a history of pancreatitis warrant particular caution, though the causal relationship between GLP-1 agonists and pancreatitis remains under investigation.

Side Effects and Safety Profile of Wegovy Weight Loss Injection

The most frequently reported side effects of Wegovy weight loss injection involve the gastrointestinal system, consistent with its mechanism of action on GLP-1 receptors in the digestive tract. In the STEP trials, nausea affected approximately 44% of participants, though this typically occurred during dose escalation and diminished over time [1]. Vomiting, diarrhoea, constipation, and abdominal discomfort represent other common gastrointestinal effects, generally mild to moderate in severity and transient in nature. The graduated dosing schedule specifically addresses these effects, allowing physiological adaptation before reaching therapeutic doses.

Less common but more serious adverse effects require awareness and monitoring. Wegovy weight loss injection carries warnings regarding potential thyroid C-cell tumours based on rodent studies, though human relevance remains uncertain and no causal link has been established in clinical use [5]. Acute pancreatitis has been reported rarely, presenting as persistent severe abdominal pain radiating to the back, and requires immediate discontinuation and medical evaluation. Hypoglycaemia may occur in patients taking concomitant antidiabetic medications, particularly insulin or sulphonylureas, necessitating dose adjustments of these agents. Gallbladder-related events, including cholelithiasis and cholecystitis, occur more frequently with substantial weight loss regardless of method, and patients should be counselled on recognising symptoms.

Managing Gastrointestinal Side Effects

Practical strategies can minimise gastrointestinal discomfort during Wegovy weight loss injection treatment. Eating smaller, more frequent meals rather than large portions reduces the sensation of fullness and associated nausea. Avoiding high-fat, fried, or heavily spiced foods during the initial weeks of treatment decreases digestive burden whilst the body adapts to slowed gastric emptying [6]. Staying well-hydrated and avoiding lying down immediately after eating further improves tolerability. If nausea persists despite these measures, prescribers may recommend temporarily maintaining the current dose for an additional week before escalating, or prescribing antiemetic medication for short-term symptom relief.

Purchasing Wegovy Weight Loss Injection from UK-Registered Pharmacies

Acquiring Wegovy weight loss injection legally in the UK requires a valid prescription issued by a registered healthcare professional following clinical assessment. At Cured Pharmacy, the process begins with a comprehensive online consultation reviewed by UK-registered prescribers who evaluate medical history, current medications, weight management goals, and suitability for semaglutide therapy. This assessment typically takes under three minutes to complete and ensures that treatment aligns with MHRA licensing and professional prescribing standards. Upon approval, genuine Novo Nordisk Wegovy is dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery across the UK.

Wegovy weight loss injection is available at Cured Pharmacy from £124.99 representing competitive UK pricing for this branded medication. Patients should be cautious of significantly lower prices that may indicate counterfeit or diverted medications—a growing concern with high-demand weight loss treatments. All Wegovy supplied through Cured Pharmacy is sourced through legitimate UK pharmaceutical supply chains, ensuring product authenticity, proper storage conditions, and full traceability. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees dispensing procedures and remains available for clinical queries throughout your treatment journey. New patients can Save £20 on their first order using code Weightlossnew, reducing the initial cost whilst accessing genuine, MHRA-approved medication.

Verifying Pharmacy Legitimacy and Medication Authenticity

When purchasing Wegovy weight loss injection online, verification of pharmacy credentials protects against counterfeit products and substandard care. Legitimate UK pharmacies display their GPhC registration number prominently—ours is 9012511, verifiable on the General Pharmaceutical Council website. Genuine Wegovy pens feature specific packaging elements including Novo Nordisk branding, batch numbers, expiry dates, and holographic security features. The medication should arrive in temperature-controlled packaging if ambient temperatures exceed safe storage ranges, and include patient information leaflets in English conforming to UK regulatory requirements.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): approved use for chronic weight management. Drug Safety Update, 16(9). [accessed 15 August 2026]
6. Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., ... & Wilding, J. P. (2020). Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity, 28(6), 1050-1061. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.